JNJ - Emergent says it is making improvements to troubled Baltimore vaccine plant

Emergent Biosolutions (EBS), whose Baltimore plant has drawn the scrutiny of the FDA, says it has initiated a comprehensive quality enhancement plan for the facility.The plant is where a manufacturing mix-up in late March ruined 15M Johnson & Johnson (JNJ) COVID-19 vaccine doses.The company says the improvements will meet or exceed FDA standards.Emergent adds it is working with both the FDA and J&J to resume production at the plant.Emergent shares are unchanged at $58.80 in premarket trading.

For further details see:

Emergent says it is making improvements to troubled Baltimore vaccine plant